The Covid Industrial Complex of Profits By Brian Simpson

While working on the Covid issue for this blog, I always wondered about just how much profit Big Pharma was making from the whole plandemic. When I hear that there will need to be multiple vaccines, well that brings out the cynic in me, especially after reading articles like this one, that predicts 9.7 billion doses by 2025. That is a lot of loot, US $132.3 billion!

https://www.reportlinker.com/p06097782/Global-COVID-19-Vaccines-Industry.html?utm_source=gnaa

“Abstract:

Global COVID-19 Vaccines Market to Reach 9.7 Billion Doses by 2025

- Global COVID-19 annual vaccine doses estimated at 11 million doses in 2020 will reach 9.7 billion doses by 2027, displaying at a CAGR of 4.8% over the analysis period 2020-2025. In terms of value, the global market is projected to reach US$132.3 billion by the year 2025 up from the US$267 million estimated in the year 2020. Vaccine doses for children under 18 years, also analyzed as part of the report, will record a projected 90.5% CAGR over the analysis period.

- Annual Doses in the U.S. to Plateau at 491 Million by 2025, While Africa Will Peak at 1.1 Billion Doses

- Annual vaccine doses administered in the U.S. will plateau at 491 million doses by 2025 after peaking at 543 million doses in the year 2023. The country will record 2.1% CAGR for the period 2020 through 2025. China and Rest of Latin America will recorded the highest growth of 8.1% and 8.7% respectively over the said analysis period. Africa will remain the last region to catch up with the vaccine race. With just 823 million annual doses in 2021, the region is projected to record over 1.1 billion annual doses by the year 2025. In terms of value, annual vaccine doses in the U.S. is estimated at US$16 billion in year 2021, while Africa at the other end of scale weighs in at just US$5 billion for the same year. India, the new epicenter of the global pandemic will record the highest annual vaccine doses of 2.2 billion only in the year 2023.

Vaccines Doses for Under 18 Years to Record 90.5% CAGR

- Global annual vaccines doses for children under 18 years estimated at 296.6 million doses in the year 2021, will reach a projected 3.5 billion doses by the year 2025, trailing a 90.5% CAGR. Regions with a large base of young population will witness the fastest growth. Middle East, Africa and Asia are all forecast to grow at 120.5%, 145.1% and 96.7% CAGR respectively. In China and India annual doses administered in this demographic cluster will increase from 109 million doses in 2021 to peak at 1.3 billion doses by the year 2025.

Select Competitors (Total 335 Featured)

• Moderna, Inc.
• Pfizer Inc./BioNTech
• AstraZeneca/University of Oxford
• Johnson & Johnson
• CanSino Biologics, Inc.
• China National Pharmaceutical Group Co., Ltd. (Sinopharm)
• Sinovac Biotech Ltd.
• Novavax, Inc.
• Inovio Pharmaceuticals
• Sanofi/GlaxoSmithKline
• Gamaleya Institute.”
• Don’t you wish you had your own vaccines company? Why, just a few good years, flog it off, and retire to some tropical paradise and forget about the struggle, let the world look after itself. No, just joking, I am here to the bitter, grim, black pilled end, ever-ready to go down with the ship, if necessary!